ImmunityBio (IBRX) Competitors $2.74 +0.10 (+3.60%) As of 01:11 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IBRX vs. BPMC, BBIO, ROIV, VRNA, RVMD, ELAN, LEGN, GRFS, TGTX, and LNTHShould you be buying ImmunityBio stock or one of its competitors? The main competitors of ImmunityBio include Blueprint Medicines (BPMC), BridgeBio Pharma (BBIO), Roivant Sciences (ROIV), Verona Pharma PLC American Depositary Share (VRNA), Revolution Medicines (RVMD), Elanco Animal Health (ELAN), Legend Biotech (LEGN), Grifols (GRFS), TG Therapeutics (TGTX), and Lantheus (LNTH). These companies are all part of the "pharmaceutical products" industry. ImmunityBio vs. Its Competitors Blueprint Medicines BridgeBio Pharma Roivant Sciences Verona Pharma PLC American Depositary Share Revolution Medicines Elanco Animal Health Legend Biotech Grifols TG Therapeutics Lantheus Blueprint Medicines (NASDAQ:BPMC) and ImmunityBio (NASDAQ:IBRX) are both mid-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations, profitability and earnings. Which has more risk & volatility, BPMC or IBRX? Blueprint Medicines has a beta of 0.89, meaning that its stock price is 11% less volatile than the S&P 500. Comparatively, ImmunityBio has a beta of 0.08, meaning that its stock price is 92% less volatile than the S&P 500. Do analysts recommend BPMC or IBRX? Blueprint Medicines currently has a consensus target price of $128.06, suggesting a potential downside of 0.16%. ImmunityBio has a consensus target price of $12.25, suggesting a potential upside of 347.90%. Given ImmunityBio's stronger consensus rating and higher possible upside, analysts plainly believe ImmunityBio is more favorable than Blueprint Medicines.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Blueprint Medicines 0 Sell rating(s) 17 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.27ImmunityBio 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20 Which has better earnings and valuation, BPMC or IBRX? Blueprint Medicines has higher revenue and earnings than ImmunityBio. Blueprint Medicines is trading at a lower price-to-earnings ratio than ImmunityBio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBlueprint Medicines$508.82M16.28-$67.09M-$2.47-51.93ImmunityBio$14.74M163.77-$413.56M-$0.58-4.72 Is BPMC or IBRX more profitable? Blueprint Medicines has a net margin of -27.70% compared to ImmunityBio's net margin of -1,310.30%. ImmunityBio's return on equity of 0.00% beat Blueprint Medicines' return on equity.Company Net Margins Return on Equity Return on Assets Blueprint Medicines-27.70% -64.60% -17.22% ImmunityBio -1,310.30%N/A -121.88% Do insiders & institutionals believe in BPMC or IBRX? 8.6% of ImmunityBio shares are held by institutional investors. 4.2% of Blueprint Medicines shares are held by company insiders. Comparatively, 76.8% of ImmunityBio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Does the media favor BPMC or IBRX? In the previous week, Blueprint Medicines had 6 more articles in the media than ImmunityBio. MarketBeat recorded 7 mentions for Blueprint Medicines and 1 mentions for ImmunityBio. Blueprint Medicines' average media sentiment score of 0.84 beat ImmunityBio's score of -1.32 indicating that Blueprint Medicines is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Blueprint Medicines 3 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ImmunityBio 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Negative SummaryImmunityBio beats Blueprint Medicines on 8 of the 15 factors compared between the two stocks. Get ImmunityBio News Delivered to You Automatically Sign up to receive the latest news and ratings for IBRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IBRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IBRX vs. The Competition Export to ExcelMetricImmunityBioMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.41B$2.90B$5.50B$9.01BDividend YieldN/A2.64%5.39%4.11%P/E Ratio-4.7221.5027.4220.07Price / Sales163.77282.64398.50109.13Price / CashN/A41.4736.1356.90Price / Book-4.807.518.015.70Net Income-$413.56M-$55.05M$3.16B$248.47M7 Day Performance-1.97%3.05%2.08%2.92%1 Month Performance0.92%5.80%4.38%5.77%1 Year Performance-56.45%6.15%35.81%21.39% ImmunityBio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IBRXImmunityBio2.074 of 5 stars$2.74+3.6%$12.25+347.9%-57.3%$2.41B$14.74M-4.72590Gap UpBPMCBlueprint Medicines1.5615 of 5 stars$128.180.0%$128.06-0.1%+16.2%$8.28B$508.82M-51.89640BBIOBridgeBio Pharma4.7148 of 5 stars$42.07+0.8%$56.67+34.7%+71.9%$7.99B$127.42M-11.91400News CoverageAnalyst ForecastInsider TradeAnalyst RevisionROIVRoivant Sciences1.9578 of 5 stars$11.63+1.5%$17.50+50.5%+3.9%$7.90B$29.05M-46.50860VRNAVerona Pharma PLC American Depositary Share2.5915 of 5 stars$96.71+2.5%$101.10+4.5%+482.7%$7.84B$118.54M-48.3630Positive NewsAnalyst ForecastRVMDRevolution Medicines4.516 of 5 stars$40.44+2.0%$67.08+65.9%-0.5%$7.50B$11.58M-10.07250Analyst RevisionELANElanco Animal Health2.3618 of 5 stars$13.37-0.7%$15.17+13.5%+5.1%$6.64B$4.43B18.069,000Analyst ForecastLEGNLegend Biotech3.2498 of 5 stars$33.81-0.6%$76.20+125.4%-19.7%$6.21B$627.24M-57.312,609News CoveragePositive NewsAnalyst ForecastGRFSGrifols4.0424 of 5 stars$8.48-3.3%$10.30+21.4%+40.2%$5.85B$7.81B7.2823,822TGTXTG Therapeutics3.6883 of 5 stars$35.99-0.1%$40.80+13.4%+98.2%$5.71B$329M149.98290LNTHLantheus4.4545 of 5 stars$80.08+1.1%$132.67+65.7%+1.4%$5.54B$1.53B22.73700Positive News Related Companies and Tools Related Companies BPMC Alternatives BBIO Alternatives ROIV Alternatives VRNA Alternatives RVMD Alternatives ELAN Alternatives LEGN Alternatives GRFS Alternatives TGTX Alternatives LNTH Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IBRX) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredA grave, grave error.President Donald Trump made headlines last month with a staggering claim. He stated that since taking offic...Porter & Company | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ImmunityBio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ImmunityBio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
